MyoKardia (MYOK) Prices 5.25M Share Common Offering at $105/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St indexes fall to two-week lows as rising bond yields, disappointing Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
MyoKardia (MYOK) PT Raised to $117 at Morgan Stanley
May 12, 2020 8:47 AM EDTMorgan Stanley analyst Jeffrey Hung raised the price target on MyoKardia (NASDAQ: MYOK) to $117.00 (from $87.00) while maintaining a Overweight rating.... More
MyoKardia (MYOK) PT Raised to $125 at Citi
May 12, 2020 5:33 AM EDTCiti analyst Mohit Bansal raised the price target on MyoKardia (NASDAQ: MYOK) to $125.00 (from $87.00) while maintaining a Buy rating.... More
MyoKardia (MYOK) Announces $450M Proposed Public Offering of Common Stock
May 11, 2020 4:02 PM EDTMyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases, today announced that it has commenced a proposed underwritten public offering to sell $450.0 million in shares of its common stock. MyoKardia expects to grant the underwriters a 30-day option to purchase up to $67.5 million in additional shares of common stock at the public offering price, less the underwriting discount. All shares of common stock will be offered by MyoKardia. The offering is... More
MyoKardia (MYOK) PT Raised to $145 at Cowen
May 11, 2020 2:47 PM EDTCowen analyst Ritu Baral raised the price target on MyoKardia (NASDAQ: MYOK) to $145.00 (from $104.00) while maintaining a Outperform rating.
The analyst commented, "As we expected, topline pivotal Ph3 oHCM EXPLORER data met its primary composite endpoint, driven by both subcomponents (NYHA class & pVO2). Stats,... More
MyoKardia (MYOK) PT Raised to $136 at Credit Suisse
May 11, 2020 12:09 PM EDTCredit Suisse analyst Martin Auster raised the price target on MyoKardia (NASDAQ: MYOK) to $136.00 (from $82.00) while maintaining a Outperform rating.
... MorePre-Open Stock Movers 05/11: (MYOK) (AMC) (AVYA) Higher; (VUZI) (UA) (PENN) Lower (more...)
May 11, 2020 9:28 AM EDTToday's Pre-Open Stock Movers:
Cellect Biotechnology Ltd. (NASDAQ: APOP) 118% HIGHER; announced the publication of an article in Bone Marrow Transplantation, a peer-reviewed medical journal )member of the Nature publishing house) covering transplantation of bone marrow in humans and published monthly by the prestigious Nature Research, entitled 'Ex-vivo FAS-ligand to Improve Allograft Safety'. The article is co-authored by researchers at Cellect and its academic partners.
MyoKardia, Inc. (Nasdaq: MYOK) 83.3% HIGHER; announced positive topline data from the companys Phase 3 pivotal EXPLORER-HCM clinical trial of... More
MyoKardia (MYOK) shares surge 88% following positive data
May 11, 2020 8:06 AM EDTMyoKardia (NASDAQ: MYOK) shares surge 88% following positive data.
... MoreMyoKardia (MYOK) to Resume Trading at 8 am
May 11, 2020 7:55 AM EDTMyoKardia (NASDAQ: MYOK) to Resume Trading at 8 am
... MoreMyoKardia (MYOK) Phase 3 EXPLORER-HCM Trial Met All Primary and All Secondary Endpoints to Treat Obstructive Hypertrophic Cardiomyopathy
May 11, 2020 7:35 AM EDTMyoKardia, Inc. (Nasdaq: MYOK) today announced positive topline data from the companys Phase 3 pivotal EXPLORER-HCM clinical trial of mavacamten for the treatment of patients with symptomatic, obstructive hypertrophic cardiomyopathy (HCM) (clinicaltrials.gov NCT03470545). Mavacamten demonstrated a robust treatment effect: the primary and all secondary endpoints of the EXPLORER trial were met with statistical significance (p0.0006 for all... More
MyoKardia (MYOK) Halted, News Pending
May 11, 2020 7:27 AM EDTMyoKardia (NASDAQ: MYOK) Halted, News Pending
... More